Lunai Bioworks Inc. LNAI
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -56.38% | -49.15% | -44.40% | -30.50% | -27.19% |
| Depreciation & Amortization | -30.69% | -19.91% | -2.14% | 13.39% | 10.66% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.32% | -50.41% | -48.65% | -36.83% | -32.26% |
| Operating Income | 57.60% | 50.51% | 48.65% | 36.83% | 32.26% |
| Income Before Tax | 98.00% | -91.45% | 0.53% | -6.09% | -101.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 98.00% | -91.45% | 0.53% | -6.09% | -101.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.00% | -91.45% | 0.53% | -6.09% | -101.31% |
| EBIT | 57.60% | 50.51% | 48.65% | 36.83% | 32.26% |
| EBITDA | 57.75% | 50.70% | 48.87% | 37.07% | 32.43% |
| EPS Basic | 98.94% | -70.87% | 26.09% | 24.12% | -21.54% |
| Normalized Basic EPS | 73.03% | 63.99% | 63.85% | 61.26% | 65.70% |
| EPS Diluted | 98.94% | -70.55% | 26.15% | 24.18% | -21.42% |
| Normalized Diluted EPS | 72.97% | 63.92% | 63.99% | 61.37% | 65.78% |
| Average Basic Shares Outstanding | 62.54% | 39.55% | 37.23% | 49.31% | 69.14% |
| Average Diluted Shares Outstanding | 62.15% | 39.21% | 37.50% | 49.64% | 69.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |